T

Tandem Clinical Research | Marrero, LA

Research site
(Unclaimed)
Location
1111 Medical Center Blvd, Marrero, Louisiana, United States of America
Site insights

Top conditions

Non-alcoholic Fatty Liver Disease (21 trials)

Fatty Liver (21 trials)

Liver Cirrhosis (8 trials)

Liver Diseases (6 trials)

Obesity (6 trials)

Top treatments

Relamorelin
Ozanimod
Guselkumab
Cenicriviroc
Tirzepatide
BMS-986036
Omalizumab
OTO-313
ABX464
LY3298176

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

45 of 86
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

Not yet enrolling
Obesity
Drug: GLY-200
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, phase 1b study designed to evaluate safety, tolerability, PK, and preliminary efficacy of APL...

Enrolling
Ulcerative Colitis
Drug: APL-1401
Drug: Placebo

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qu...

Enrolling
Diabetic Peripheral Neuropathic Pain
Drug: Placebo
Drug: RTA 901

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: MGL-3196

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod
Other: Placebo

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling
Depressive Disorder, Major
Anhedonia
Other: Placebo
Drug: Aticaprant

This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks in Part A or 24 weeks in Part B.

Enrolling
Nonalcoholic Steatohepatitis (NASH)
Drug: BOS-580
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.

Enrolling
Eosinophilic Esophagitis
Drug: Matching Placebo
Biological: barzolvolimab

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Enrolling
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

Active, not recruiting
Crohn Disease
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 1

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severe...

Enrolling
Colitis, Ulcerative
Drug: JNJ-77242113
Drug: Placebo

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Enrolling
Type 2 Diabetes
Drug: Dapagliflozin
Drug: Orforglipron

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of gus...

Active, not recruiting
Crohn's Disease
Drug: Guselkumab Dose 3
Drug: Ustekinumab

The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic St...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: Tirzepatide

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Biological: ExPEC9V
Other: Placebo

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting in...

Active, not recruiting
SARS-CoV-2 Infection
Drug: S-217622
Drug: Placebo

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling
Diabetic Gastroparesis
Drug: CIN-102 Dose 1
Drug: CIN-102 Dose 2

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Active, not recruiting
Obesity
Drug: Garetosmab
Drug: Matching Placebo-Trevogrumab
Locations recently updated

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

Trial sponsors

Janssen logo

Janssen (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems